Market
Top Sales Region for PTC518 in First Two Years?
2
Resolution / Starting Odds
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%
Sales reports from PTC Therapeutics and Novartis
Story
PTC Therapeutics Secures $2.9B Deal with Novartis for Huntington's Drug, $1B Upfront
Dec 2, 2024, 01:09 PM
PTC Therapeutics Inc. has entered into a significant licensing agreement with Novartis AG, focusing on the development of PTC518, an experimental drug for Huntington's disease. The deal, which could be worth up to $2.9 billion, includes an upfront payment of $1 billion to PTC Therapeutics. Under the terms, Novartis will share U.S. profits and losses with PTC Therapeutics on a 40/60 basis, with PTC receiving 40%. This collaboration marks Novartis's renewed interest in Huntington's disease treatments. The agreement also involves global licensing and collaboration for the drug's development, with Novartis taking the lead in further development efforts.
View original story
Similar markets
$500 million to $1 billion • 25%
Less than $500 million • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Three or more • 25%
Two • 25%
One • 25%
None • 25%
Europe • 25%
Other • 25%
Asia-Pacific • 25%
North America • 25%
Sub-Saharan Africa • 25%
South America • 25%
Southeast Asia • 25%
Other • 25%
North America • 25%
Africa • 25%
Asia • 25%
Europe • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
Other • 25%
China • 25%
European Union • 25%
United States • 25%
Asia • 25%
Africa • 25%
Europe • 25%
North America • 25%
European Union • 25%
Other • 25%
United States • 25%
Asia • 25%
Latin America • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Europe • 25%
Other • 25%
Asia-Pacific • 25%
North America • 25%